絞り込み

16641

広告

「医療マンガ大賞」、受賞作品が決定 (日経BP)

神奈川県横浜市は今年、医療広報の一環として、漫画を活用した取り組み「医療マンガ大賞」を創設した(関連記事:医師と患者のギャップを埋める「医療マンガ大賞」創設)。...

  1. タイの大型肉食恐竜、新種と判明 (デイリ...
  2. 映画を通じた交流を 大阪韓国映画祭始まる...
  3. だんだん小さく、やがて視野の外…「さよな...
  4. 新種の大型肉食恐竜「シャムラプトル・スワ...

ニュース一覧

Rationale and design of the German-speaking myeloma multicenter group (GMMG) trial HD6: a randomized phase III trial on the effect of elotuzumab in VRD induction/consolidation and lenalidomide maintenance in patients with newly diagnosed myeloma.

著者 Salwender H , Bertsch U , Weisel K , Duerig J , Kunz C , Benner A , Blau IW , Raab MS , Hillengass J , Hose D , Huhn S , Hundemer M , Andrulis M , Jauch A , Seidel-Glaetzer A , Lindemann HW , Hensel M , Fronhoffs S , Martens U , Hansen T , Wattad M , Grae
BMC Cancer.2019 May 28 ; 19(1):504.
この記事をPubMed上で見るPubMedで表示
この記事をGoogle翻訳上で見る Google翻訳で開く

スターを付ける スターを付ける     (98view , 0users)

Full Text Sources

Medical

Despite major advances in therapy, multiple myeloma is still an incurable malignancy in the majority of patients. To increase survival, deeper remissions (i.e. CR) translating into longer PFS need to be achieved. Incorporation of new drugs (i.e. bortezomib and lenalidomide) as induction and maintenance treatment in an intensified treatment concept, including high dose melphalan (200 mg/m), has resulted in increased CR rates, and is considered the standard of care for younger patients. Elotuzumab in combination with lenalidomide and dexamethasone has given better results as lenalidomide and dexamethasone alone in a phase III trial. The GMMG-HD6 trial will be the first phase III trial investigating the role of elotuzumab in combination with bortezomib, lenalidomide and dexamethasone (VRD) induction/consolidation and lenalidomide maintenance within a high dose concept.
PMID: 31138244 [PubMed - in process]
印刷用ページを開く Endnote用テキストダウンロード